FGFR1 is an important prognostic factor in oral leukoplakia and tongue squamous cell carcinoma
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
MARIZ, Bruno Augusto Linhares Almeida
SA, Raisa Sales de
ARAUJO, Anna Luiza Damaceno
FERNANDES, Carla Isabelly Rodrigues
MARIANO, Fernanda Viviane
SANTOS-SILVA, Alan Roger
LOPES, Marcio Ajudarte
VARGAS, Pablo Agustin
ALMEIDA, Oslei Paes de
Citação
JOURNAL OF ORAL PATHOLOGY & MEDICINE, v.52, n.2, p.119-126, 2023
Resumo
Background: Fibroblast growth factor receptor 1 is a potential prognostic factor for tongue squamous cell carcinoma and is associated with oral epithelial dysplasia grade in oral leukoplakia.Methods: Thirty cases of tongue squamous cell carcinoma and 30 cases of oral leukoplakia were analyzed. Fibroblast growth factor receptor 1 and phosphorylated Akt protein expression were analyzed by immunohistochemistry and quantified using a digital algorithm. Fibroblast growth factor receptor 1 gene amplification was analyzed by fluorescent in situ hybridization in the tongue squamous cell carcinoma cases.Results: Clinical appearance and dysplasia grade were correlated with oral leukoplakia malignant transformation. Oral leukoplakia cases presenting high fibroblast growth factor receptor 1 expression showed a higher risk of malignant transformation (p = 0.016, HR: 7.3, 95% CI: 1.4-37.4). Phosphorylated Akt showed faint to no expression in oral leukoplakia, which did not correlate with dysplasia grade or malignant transformation. High expression of fibroblast growth factor receptor 1 and phosohorylated Akt were associated with poor overall survival and disease-free survival in tongue squamous cell carcinoma, although only fibroblast growth factor receptor 1 expression was significantly associated with poor overall survival (p = 0.024; HR: 4.9, 95% CI: 1.2-19.9). Cases presenting double fibroblast growth factor receptor 1/phosphorylated Akt overexpression (n = 8) showed markedly impaired overall survival (p = 0.020; HR: 6.4, 95% CI: 1.3-31.1) and disease-free survival (p = 0.001, HR: 13.0, 95% CI: 3.0-55.7). Fibroblast growth factor receptor 1 amplification was observed in 16.6% of tongue squamous cell carcinoma cases, being correlated with vascular and neural invasion (p = 0.001 and 0.017, respectively), but not with fibroblast growth factor receptor 1 protein expression, overall survival, or disease-free survival.Conclusion: Fibroblast growth factor receptor 1 protein expression is an important prognostic factor in oral leukoplakia and tongue squamous cell carcinoma.
Palavras-chave
AKT, FGFR1, immunohistochemistry, oral cancer, oral leukoplakia
Referências
- Aguirre-Urizar JM, 2021, ORAL DIS, V27, P1881, DOI 10.1111/odi.13810
- Bogatyrova O, 2021, EUR J CANCER, V151, P136, DOI 10.1016/j.ejca.2021.04.005
- Clauditz TS, 2018, J CANCER RES CLIN, V144, P53, DOI 10.1007/s00432-017-2528-x
- Datta J, 2017, MOL CANCER THER, V16, P614, DOI 10.1158/1535-7163.MCT-15-1010
- Dubot C, 2018, EUR J CANCER, V91, P47, DOI 10.1016/j.ejca.2017.12.016
- El-Naggar A.K., 2017, WHO CLASSIFICATION H, V4th ed.
- Freier K, 2007, ORAL ONCOL, V43, P60, DOI 10.1016/j.oraloncology.2006.01.005
- Goke F, 2013, MODERN PATHOL, V26, P1298, DOI 10.1038/modpathol.2013.58
- Hu Y, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251202
- IARC, 2021, GLOBAL CANC OBSERVAT
- Iida M, 2020, MUTAT RES-FUND MOL M, V819, DOI 10.1016/j.mrfmmm.2020.111690
- Koole K, 2016, CLIN CANCER RES, V22, P3884, DOI 10.1158/1078-0432.CCR-15-1874
- Krook MA, 2021, BRIT J CANCER, V124, P880, DOI 10.1038/s41416-020-01157-0
- Kujan O, 2006, ORAL ONCOL, V42, P987, DOI 10.1016/j.oraloncology.2005.12.014
- Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129
- Mariz BALA, 2019, HISTOPATHOLOGY, V74, P311, DOI 10.1111/his.13739
- Mello FW, 2020, CRIT REV ONCOL HEMAT, V153, DOI 10.1016/j.critrevonc.2020.102986
- Monteiro L, 2021, ORAL DIS, V27, P1977, DOI 10.1111/odi.13747
- Muller S, 2018, OR SURG OR MED OR PA, V125, P591, DOI 10.1016/j.oooo.2018.02.012
- Peng CH, 2015, ONCOTARGET, V6, P19891, DOI 10.18632/oncotarget.4336
- Rusthoven K, 2008, CANCER-AM CANCER SOC, V112, P345, DOI 10.1002/cncr.23183
- Rusthoven KE, 2010, J ORAL MAXIL SURG, V68, P584, DOI 10.1016/j.joms.2009.03.056
- Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
- Schuler M, 2019, LANCET ONCOL, V20, P1454, DOI 10.1016/S1470-2045(19)30412-7
- Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310
- Speight PM, 2018, OR SURG OR MED OR PA, V125, P612, DOI 10.1016/j.oooo.2017.12.011
- Starska K, 2018, CELL ONCOL, V41, P253, DOI 10.1007/s13402-017-0367-z
- Touat M, 2015, CLIN CANCER RES, V21, P2684, DOI 10.1158/1078-0432.CCR-14-2329
- Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
- Warnakulasuriya S, 2021, ORAL DIS, V27, P1862, DOI 10.1111/odi.13704
- Wheler Jennifer J, 2016, Oncoscience, V3, P164, DOI 10.18632/oncoscience.307
- Young RJ, 2013, ORAL ONCOL, V49, P576, DOI 10.1016/j.oraloncology.2013.01.006